Clinical Trial Update: Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of Axatilimab plus standard of care to prevent graft-versus-host disease after allogeneic hematopoietic ste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Cancer

Drugs mentioned

• Axatilimab (axatilimab)

Snippet

Sponsor: Mayo Clinic | Conditions: Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Status: NOT_YET_RECRUITING